Insights

Strategic Partnerships Arcturus Therapeutics has formed key partnerships with companies like CSL Seqirus and Achilles Therapeutics to develop personalized cancer vaccines and mRNA vaccines targeting COVID-19 and influenza. Exploring collaboration opportunities with these partners could lead to new sales avenues.

Investor Interest Recent investments by firms like Great Lakes Advisors and Ajovista in Arcturus Therapeutics show growing investor confidence in the company's mRNA medicines and vaccines. Leveraging this interest to attract more investors and funding can provide resources for expanding sales operations.

Cutting-Edge Technologies Arcturus Therapeutics utilizes innovative technologies such as LUNAR® lipid-mediated delivery and STARR® mRNA Technology. Highlighting the cutting-edge nature of these technologies in sales pitches can attract customers looking for advanced solutions in mRNA therapeutics.

Financial Health With a revenue range of $10M to $50M and additional funding of $9M, Arcturus Therapeutics demonstrates financial stability. This financial health can instill confidence in potential clients regarding the company's ability to deliver on commitments and invest in R&D for future products.

Market Leadership Arcturus Therapeutics leads in mRNA medicines development, evident from being the first to create a self-amplifying mRNA COVID vaccine. Highlighting this market leadership in communications with potential clients can position the company as a reliable partner for innovative therapeutic solutions.

Arcturus Therapeutics Tech Stack

Arcturus Therapeutics uses 8 technology products and services including SiteCatalyst, Google Charts, Modernizr, and more. Explore Arcturus Therapeutics's tech stack below.

  • SiteCatalyst
    Analytics
  • Google Charts
    Javascript Graphics
  • Modernizr
    Javascript Libraries
  • Google Maps
    Maps
  • HTTP/3
    Miscellaneous
  • Office 365
    Office Suites
  • Nginx
    Web Servers
  • OpenResty
    Web Servers

Media & News

Arcturus Therapeutics's Email Address Formats

Arcturus Therapeutics uses at least 1 format(s):
Arcturus Therapeutics Email FormatsExamplePercentage
firstlast@arcturusrx.comJohnDoe@arcturusrx.com
25%
last@arcturusrx.comDoe@arcturusrx.com
25%
firstl@arcturusrx.comJohnD@arcturusrx.com
25%
first.l@arcturusrx.comJohn.D@arcturusrx.com
25%

Frequently Asked Questions

Where is Arcturus Therapeutics's headquarters located?

Minus sign iconPlus sign icon
Arcturus Therapeutics's main headquarters is located at 10628 Science Center Drive Suite 250 San Diego, CA 92121 US. The company has employees across 4 continents, including North AmericaEuropeAsia.

What is Arcturus Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact Arcturus Therapeutics's main corporate office by phone at +1-858-242-1526. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Arcturus Therapeutics's stock symbol?

Minus sign iconPlus sign icon
Arcturus Therapeutics is a publicly traded company; the company's stock symbol is ARCT.

What is Arcturus Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
Arcturus Therapeutics's official website is arcturusrx.com and has social profiles on LinkedIn.

How much revenue does Arcturus Therapeutics generate?

Minus sign iconPlus sign icon
As of April 2024, Arcturus Therapeutics's annual revenue reached $35M.

What is Arcturus Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
Arcturus Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Arcturus Therapeutics have currently?

Minus sign iconPlus sign icon
As of April 2024, Arcturus Therapeutics has approximately 195 employees across 4 continents, including North AmericaEuropeAsia. Key team members include Chief Financial Officer And Board Of Director: A. S.Chief Strategy Officer Cso: R. D.Chief Technology Officer Cto: D. V.. Explore Arcturus Therapeutics's employee directory with LeadIQ.

What industry does Arcturus Therapeutics belong to?

Minus sign iconPlus sign icon
Arcturus Therapeutics operates in the Biotechnology Research industry.

What technology does Arcturus Therapeutics use?

Minus sign iconPlus sign icon
Arcturus Therapeutics's tech stack includes SiteCatalystGoogle ChartsModernizrGoogle MapsHTTP/3Office 365NginxOpenResty.

What is Arcturus Therapeutics's email format?

Minus sign iconPlus sign icon
Arcturus Therapeutics's email format typically follows the pattern of . Find more Arcturus Therapeutics email formats with LeadIQ.

How much funding has Arcturus Therapeutics raised to date?

Minus sign iconPlus sign icon
As of April 2024, Arcturus Therapeutics has raised $9M in funding. The last funding round occurred on Sep 26, 2023.

When was Arcturus Therapeutics founded?

Minus sign iconPlus sign icon
Arcturus Therapeutics was founded in 2013.
Arcturus Therapeutics

Arcturus Therapeutics

Biotechnology ResearchCalifornia, United States51-200 Employees

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). 

Section iconCompany Overview

Headquarters
10628 Science Center Drive Suite 250 San Diego, CA 92121 US
Phone number
+1-858-242-1526
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
ARCT
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
51-200

Section iconFunding & Financials

  • $9M

    Arcturus Therapeutics has raised a total of $9M of funding over 9 rounds. Their latest funding round was raised on Sep 26, 2023.

  • $10M$50M

    Arcturus Therapeutics's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $9M

    Arcturus Therapeutics has raised a total of $9M of funding over 9 rounds. Their latest funding round was raised on Sep 26, 2023.

  • $10M$50M

    Arcturus Therapeutics's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.